CD36, a lipid transporter and platelet signaling activator, promotes TNBC metastasis,[22, 23] while Serpine1, a fibrinolysis inhibitor, is linked to platelet hyperactivation and poor breast cancer prognosis.[24, 25] KEGG analysis revealed modulation of the TGF‐β, p53, HIF‐1, and AMPK signaling pathways (Figure 4i). This evidence concerns the gene CD36 and breast cancer.